Protecting Pyrazinamide

Protecting Pyrazinamide and Fluoroquinolones for successful multi-drug resistant tuberculosis (MDR-TB) treatment

Objective

The objective of the study is to assess the frequency of additional drug resistance under sub-optimal treatment for drug-resistant tuberculosis.


Description

Even when correctly managed, following international and national guidelines, due to the complexity of (tuberculosis) TB diagnostics and delay of the identification of resistance, a proportion of patients will initially receive inappropriate first line therapy. The precise contribution this under-treatment makes to the generation of resistance is unknown.

 

We will study a cohort from Moldova and Belarus, countries with a high frequency of drug resistance in TB patients.

 

We will recruit patients who will start directly on appropriate therapy and a matched group that will initially receive inappropriate therapy. Paired sputum cultures obtained at the time of diagnosis, and at the moment drug resistance is detected will be assessed for additional drug resistance. Results will be directly relevant for future treatment and monitoring guidelines.


AIGHD Research Lead

Assoc. Prof. Frank van Leth


Partners

RIVM

University Hospital Groningen

TB treatment center Belarus

TB treatment center Moldova


Contact info

Richard Anthony (richard.anthony@rivm.nl)


Funders

ZONMw


Countries

Netherlands

Moldova

Belarus